Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 153Melanoma 133Lymphoma 124Prostatic Neoplasms 123Carcinoma, Non-Small-Cell Lung 113Multiple Myeloma 106Carcinoma, Renal Cell 92Ovarian Neoplasms 88Leukemia, Myeloid, Acute 83Sarcoma 82Lung Neoplasms 80Leukemia, Lymphocytic, Chronic, B-Cell 80Leukemia 79Colorectal Neoplasms 79Colonic Neoplasms 74Rectal Neoplasms 71Lymphoma, Non-Hodgkin 69Pancreatic Neoplasms 68Carcinoma, Ovarian Epithelial 66Neoplasms 65Lymphoma, Large B-Cell, Diffuse 65Brain Neoplasms 65Precursor Cell Lymphoblastic Leukemia-Lymphoma 64Lymphoma, Follicular 58Kidney Neoplasms 58Glioblastoma 57Fallopian Tube Neoplasms 54Carcinoma, Hepatocellular 51Lymphoma, Mantle-Cell 50Central Nervous System Neoplasms 50

Interventions

Zidovudine 1Acyclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NIH × AIDS-Related Opportunistic Infections × Clear all
NCT00000712 2021-11-04

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
400 enrolled

Acquired Immunodeficiency Syndrome, Cytomegalovirus Infections, Herpesviridae Infections, HIV Infections, AIDS-Related Opportunistic Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡